drugset / Trial / NCT00427700

Induction of Ovulation With Raloxifene or Clomiphene Citrate in Polycystic Ovarian Syndrome

NCT00427700 ↗

Phase 3 Completed 82 enrolled Hospital de Clinicas de Porto Alegre
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The Polycystic Ovarian Syndrome (PCOS) is a common disorder related to ovulation problems. Clomiphene citrate (CC) is the drug of first choice for this condition. Nevertheless, CC has a detrimental effect over uterine receptivity. Raloxifene is a Selective Estrogen Receptor Modulator, that does not have a detrimental effect over the endometrium, and also increase the serum levels of FSH, thus, inducting ovulation. The objective of this study is to compare the ovulation rate in PCOS patients between clomiphene citrate and raloxifene in a double blind randomized trial.

Timeline

Start
2008-08
Primary completion
2009-08
Completion
2009-08

Outcome

Missed primary endpoint

registry analysis (unspecified test); Clomiphene vs Raloxifene; p = 0.3; Mean Difference (Final Values) 12 (95% CI -9 to 33); Fisher Exact NCT00427700 ↗

paper There were no statistically significant differences between the groups in ovulation rates per an intention-to-treat analysis based on ultrasound alone PMID 21782166 ↗

Publications

Drugs

EvaluationDrugModalityDoseRoute
Comparator Clomiphene Citrate Other / unclassified 100 mg Oral
Subject Raloxifene Other / unclassified 100 mg Oral